Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Amgen had argued the board is unconstitutional because its actions conflict with federal law and would regulate business ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...